8-KEarnings & ResultsLeadership ChangesExhibits & Filings

VERTEX PHARMACEUTICALS INC / MA 8-K Report, Financial Results (Feb 10, 2025)

Filed February 10, 2025For Securities:VRTX

Summary

Vertex Pharmaceuticals Inc. (VRTX) filed an 8-K on February 10, 2025, to announce two significant corporate events. The company is reporting its financial results for the fourth quarter and full year ended December 31, 2024, via a press release furnished as an exhibit. While specific financial figures are not detailed in the 8-K itself, investors should refer to Exhibit 99.1 for a comprehensive overview of the company's performance. In addition to the financial update, Vertex is undergoing a key leadership transition. Stuart A. Arbuckle, Executive Vice President and Chief Operating Officer, will retire effective July 1, 2025. Concurrently, Charles F. Wagner, Jr., currently Executive Vice President and Chief Financial Officer, will be appointed Chief Operating Officer, while retaining his CFO responsibilities. Duncan J. McKechnie, currently SVP and Head of the North America Commercial team, will step into the role of Chief Commercial Officer. Both executive appointments are also effective July 1, 2025, reflecting a strategic reshuffling of senior leadership.

Key Highlights

  • 1Vertex Pharmaceuticals announced its financial results for the three and twelve months ended December 31, 2024, via a press release filed as Exhibit 99.1.
  • 2Stuart A. Arbuckle, Executive Vice President and Chief Operating Officer, is set to retire on July 1, 2025.
  • 3Charles F. Wagner, Jr. has been appointed as the new Chief Operating Officer, effective July 1, 2025, and will continue in his role as Executive Vice President and Chief Financial Officer.
  • 4Duncan J. McKechnie will assume the position of Chief Commercial Officer, effective July 1, 2025.
  • 5New employment and change of control agreements have been established for Mr. Wagner, detailing compensation, bonus structure, and severance benefits.
  • 6Mr. McKechnie brings extensive experience in commercial strategy and has been instrumental in recent product launches, including CASGEVY and JOURNAVX.

Frequently Asked Questions

The company's consolidated financial results for the three and twelve months ended December 31, 2024, are detailed in a press release furnished as Exhibit 99.1 to this 8-K filing.

The announced changes involve the retirement of the current COO and the appointment of a new COO and CCO. Charles F. Wagner, Jr. (current CFO) will take on the COO role while remaining CFO, and Duncan J. McKechnie will become the Chief Commercial Officer. These appointments are effective July 1, 2025, and represent a transition in key executive positions.

Mr. Wagner's new employment agreement includes a base salary of $1,000,000 and a target annual bonus of 100% of his base salary. The agreement also outlines severance provisions in case of termination without cause or for good reason, including salary, bonus continuation, and accelerated vesting of equity awards. Details on change of control provisions are also included.

Mr. McKechnie has over 30 years of industry experience and has been with Vertex for approximately 12 years, holding significant commercial leadership roles. He has been a key figure in the successful launches of Vertex's cystic fibrosis medicines, CASGEVY, and JOURNAVX, and also oversees global market access teams. His extensive experience in commercial strategy and product launches makes him a strong candidate for CCO.